
Analyst Yigal Nochomovitz from Citi maintained a Buy rating on IDEAYA Biosciences and keeping the price target at $66.00. Yigal Nochomovitz gave his rating based on several factors, including IDEAYA’s
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences | 30.36 | -2.98 | -8.94% |
| Name | Price | % Change | |
|---|---|---|---|
| $30.36 | -8.94% |

Analyst Yigal Nochomovitz from Citi maintained a Buy rating on IDEAYA Biosciences and keeping the price target at $66.00. Yigal Nochomovitz gave his rating based on several factors, including IDEAYA’s

Ideaya announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 – DLL3-targeting Topo-I-payload antibody drug conjugate, or ADC, in previously treated neuroendocrine carcinomas, or NEC. Ideaya is

IDEAYA Biosciences (IDYA) announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase, CDK, inhibitor designed to address the loss of CDKN2A-mediated tumor suppressor function in cancer. CDKN2A-deficiency

Ideaya Biosciences ($IDYA) announced an update on their ongoing clinical study. Study Overview: IDEAYA Biosciences is evaluating its OptimUM-11 study, officially titled “A Randomized, Phase 3, Open-label Study of Adjuvant

Mizuho lowered the firm’s price target on Ideaya Biosciences (IDYA) to $39 from $44 and keeps an Outperform rating on the shares following the Q3 report. Published first on TheFly

Citi raised the firm’s price target on Ideaya Biosciences (IDYA) to $66 from $65 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source

RBC Capital lowered the firm’s price target on Ideaya Biosciences (IDYA) to $45 from $48 and keeps an Outperform rating on the shares after its Q3 results. All programs continue

Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $63 from $60 and keeps an Outperform rating on the shares. The firm notes the company reported third quarter

Guggenheim lowered the firm’s price target on Ideaya Biosciences (IDYA) to $52 from $57 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source

Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $57 from $59 and keeps a Buy rating on the shares. The company’s Q3 and the firm’s 1×1 with
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Assigned | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 4, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Assigned | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Oct 26, 2026 | ||||
| buy | Reiterated | Oct 26, 2026 | ||||
| buy | Reiterated | Oct 26, 2026 | ||||
| buy | Initiated | Oct 15, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 23, 2027TBA | $2.94B | $-1.20 | $15.52M | 0.44 | -6.82 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.